Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2A Trial of ENB 003 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2A Trial of ENB 003 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ENB 003 (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Fallopian tube cancer; Head and neck cancer; Lipoma; Male breast cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Sarcoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms ENBolden; ENBOLDEN-101
  • Sponsors ENB Therapeutics

Most Recent Events

  • 07 Nov 2023 According to an ENB Therapeutics media release, the company is expected to start phase 2 of this study in first half of 2024.The trial will enroll MSS primary PROC, as well as MSS pancreatic cancer patients and patients with other advanced solid tumors that have failed standard of care.
  • 07 Nov 2023 According to an ENB Therapeutics media release, data from this study was presented on November 3, 2023 at a poster session at the SITC 2023 meeting, was held November 1-5, in San Diego, California, USA.
  • 07 Nov 2023 Results published in the ENB Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top